Tremor
TrialsCompanies

Not investment advice.

Tremor shows what changed in public records. It never tells anyone to buy or sell. Many trial edits are harmless paperwork. Data from ClinicalTrials.gov, the SEC, and the Federal Register.

PrivacyTerms

REGNRegeneron PharmaceuticalsSigning up patients

A Trial to Study if REGN17372 in Combination With Linvoseltamab is Tolerable for Adult Participants With Relapsed/Refractory Multiple Myeloma

Relapsed Refractory Multiple Myeloma (RRMM)

5Calmworry score, out of 100

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

  • 5 insiders sold shares within a month

    Since Nov 4, 2026 · was worth 5, fading over time

    +4.8
Worry score5

Score over time

Stage
Phase 1/2
Patients
150 (planned)
Started
Mar 26, 2026
Main results expected
Sep 30, 2033
Fully finished
Sep 30, 2033
Results posted
not yet

What counts as success

The trial's main goal(s), called the “primary outcome.”

  • Occurrence of Dose Limiting Toxicities (DLTs) from the first dose of REGN17372 in combination with linvoseltamab

    Measured over: Up to 35 days

  • Occurrence of Treatment Emergent Adverse Events (TEAEs) associated with REGN17372 in combination with linvoseltamab

    Measured over: Up to 5 years

  • Severity of TEAEs associated with REGN17372 in combination with linvoseltamab

    Measured over: Up to 5 years

  • Very Good Partial Response (VGPR) or better as determined by the investigator using the International Myeloma Working Group (IMWG) response criteria in patients receiving combination study drugs

    Measured over: Within 12 weeks of starting cycle 1

  • VGPR or better as determined by the investigator using the IMWG response criteria in patients receiving Linvoseltamab monotherapy

    Measured over: Within 12 weeks of starting cycle 1

  • Partial Response (PR) or better as determined by the investigator using the IMWG response criteria in patients receiving combination study drugs

    Measured over: Within 12 weeks of starting cycle 1

  • PR or better as determined by the investigator using the IMWG response criteria in patients receiving Linvoseltamab monotherapy

    Measured over: Within 12 weeks of starting cycle 1

Changes Tremor has spotted

No changes since Tremor started watching this trial.
Show details (technical version)

Score inputs

  • insider_selling_cluster: base 5, now 4.8, since 2026-11-04, fades (half-life)

Raw record changes

  • none yet

Trial ID NCT07455851 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC

See the official record on ClinicalTrials.gov (NCT07455851) ↗